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Willem A NolenAbstract
With two recent systematic reviews and meta-analyses on the efficacy of lithium compared to placebo and other
treatment options, it can now be concluded that lithium is the only drug that has been shown efficacious in the
prevention of any mood episodes, manic episodes and depressive episodes in randomised trials not enriched for
prior response to and tolerance of lithium. It is argued that lithium should be recommended as the single preferred
first-line drug in the long-term treatment of bipolar disorder.
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Among the many options for the long-term treatment of
bipolar disorder, lithium is the oldest drug. After its ini-
tial use by the Danish neurologist Lange in the nine-
teenth century and its subsequent discovery by the
Australian psychiatrist Cade in 1949, the efficacy of lith-
ium was finally established by Schou and his Danish
colleagues in the 1960s which led to its registration in
Europe and the US as well as many other countries in
the 1970s (Bech 2006). Since then, several other drugs
have become available as alternatives, of which the anti-
convulsants carbamazepine, valproate and lamotrigine
and several atypical antipsychotics have also been regis-
tered for the long-term treatment of bipolar disorder.
Subsequently, all registered drugs also found their place
in guidelines, supported by data from randomised
placebo-controlled clinical trials and systematic reviews
and meta-analyses, including a meta-analysis on lithium
versus placebo which found that lithium did prevent any
mood episodes and manic episodes, but was not signifi-
cantly better than placebo in the prevention of depres-
sive episodes (Geddes et al. 2004).Correspondence: w.a.nolen@umcg.nl
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in any medium, provided the original work is pOverall, these data led to recommendations in most
guidelines for more than one drug as first-line treatment
for the long-term treatment of bipolar disorder. For in-
stance, the latest US APA guideline from 2002 (!) recom-
mends lithium or valproate and as possible alternatives
lamotrigine, carbamazepine, oxcarbazepine and ongoing
antipsychotic treatment (American Psychiatric Associ-
ation 2002); the UK NICE guideline from 2006 lithium,
olanzapine or valproate (National Institute for Health
and Care Excellence (NICE) 2006); the updated WFSBD
guideline from 2012 ‘based on strongest level of evidence
for efficacy and a good risk-benefit ratio’ aripiprazole,
lamotrigine, lithium and quetiapine (Grunze et al. 2013);
and finally the updated Canadian CANMAT and ISBD
guideline from 2013 lithium, valproate, olanzapine, que-
tiapine, lamotrigine, risperidone long-acting injection
(LAI) and ziprasidone (Yatham et al. 2013).
In 2011, the so far largest long-term study on the effi-
cacy of lithium was published (Weisler et al. 2011). In
this double-blind trial, bipolar I patients who had
responded to and had tolerated quetiapine were rando-
mised to continue with quetiapine or to switch to lith-
ium or placebo. The results showed that both quetiapine
and lithium did prevent any mood episodes, manic epi-
sodes and depressive episodes. Quetiapine was also more
effective than lithium (in the prevention of any moodn Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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be interpreted with caution as the study design was
enriched for quetiapine (see above) but not for lithium.
Only the WFSBP and the CANMAT/ISBD guidelines
did include the Weisler et al. 2011 trial, while the
WFSBP guideline also concluded that lithium was the
only drug with the strongest level of evidence (level A
for any mood episodes, manic episodes and depressive
episodes) in non-enriched samples.
Two recent meta-analyses further looked at the evi-
dence of lithium. In this journal, Severus et al. (2014)
published an update and extension of the meta-analysis
by Geddes et al. from 2004. With seven placebo-
controlled trials, i.e. two more than in 2004 including
the Weisler et al. 2014 trial, they now found that lithium
not only prevents any mood episodes and manic epi-
sodes but also prevents depressive episodes. This finding
was further supported by a network meta-analysis in-
cluding 33 randomised controlled trials examining 17
treatments (both monotherapies and combination ther-
apies) by Miura et al. (2014). Of the monotherapies, only
lithium and quetiapine were found to prevent any mood
episodes, manic episodes and depressive episodes when
compared to placebo, with the notion that the evidence
for lithium is based almost completely on trials with a
non-enriched design and for quetiapine only on trials
with enriched designs. Both meta-analyses also looked at
tolerance of lithium (more dropouts due to adverse
events with lithium than with placebo) and at overall
satisfaction with treatment (more completers with lith-
ium than with placebo).
The conclusions of both meta-analyses are rather simi-
lar. Severus et al. state that ‘with no other drug available
having such ample and consistent evidence for its effi-
cacy, lithium remains the most valuable treatment op-
tion in this indication’, and Miura et al. conclude that
‘lithium seems to be the most reasonable candidate for a
first-line option for the long-term treatment of bipolar
disorder’. This raises the question whether lithium
should indeed be recommended as the single preferred
first-line treatment. Indeed, the recent 2014 update of
the NICE guideline (with their own meta-analyses) rec-
ommends to ‘offer lithium as a first-line, long-term
pharmacological treatment for bipolar disorder’, while
regarding the other alternatives, the guideline continues
as follows: ‘if lithium is ineffective, consider adding val-
proate or if lithium is poorly tolerated, or is not suitable
(for example, because the person does not agree to rou-
tine blood monitoring), consider valproate or olanzapine
instead or, if it has been effective during an episode of
mania or bipolar depression, quetiapine’. Thus, despite
these considerations, the National Institute for Health
and Care Excellence (NICE) (2014) guideline recom-
mends lithium as the first option.One of the major limitations of all meta-analyses is
that while they looked at efficacy, tolerability and overall
satisfaction, their scope was not more than 2 years.
However, when choosing a drug for long-term if not life-
long treatment, one should look at efficacy and safety
not only during the first years but also thereafter. The
use of lithium over more than 10 years is associated with
the risk of kidney dysfunction and the use of atypical an-
tipsychotics with metabolic syndrome and an increased
mortality risk due to cardiovascular problems. Although
it has not yet been established how these late adverse ef-
fects have an impact on the long-term safety of lithium
and the atypical antipsychotics as its major alternatives,
the assumption is that also over 10 or more years the
safety of lithium is at least in balance with that of most
atypical antipsychotics. However, it would be interesting
to see studies in patients with bipolar disorder looking at
mortality during treatment with lithium and its alterna-
tives over more than 10 years such as has already been
done with clozapine versus other antipsychotics in pa-
tients with schizophrenia (Tiihonen et al. 2009).
In the meantime, I concur with the conclusions of
both meta-analyses supporting the recommendation in
the NICE guideline that lithium, given its evidence base
from trials with a non-enriched design and its relative
safety, should be the single first-line treatment. Whether
or not this conclusion will be supported by most experts
in the field of lithium will become clear in 2016 when
the recently started ISBD task force on the use of lith-
ium will present its report.
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